Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis

European Respiratory Journal

Volumn 35, Issue 2, 2010, Pages 381-390

  Scherf, D B ^a   Dally, H ^a   Muller P ^a   Werle Schneider, G ^a   Jager B ^a   Edler, L ^a   Tuengerthal, S ^b   Fischer, J R ^c   Drings, P ^b   Bartsch, H ^a   Risch, A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Klinik Lowenstein   (Germany)

Author keywords

Apoptosis; Lung cancer chemotherapy; Matrix metalloproteinase; Pharmacogenetics; Polymorphism

Indexed keywords

ETOPOSIDE; GELATINASE A; GELATINASE B; GEMCITABINE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; PLATINUM; STROMELYSIN;

ADULT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; DISEASE SEVERITY; FEMALE; GENE; HETEROZYGOTE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGED; ALLELES; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 76149142487     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00125608     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Van Cleave JH, Cooley ME. Lung cancer. In: Van Cleave JH, Cooley ME, eds. A Cancer Sourcebook for Nurses. Sudbury, MA, Jones and Bartlett Publishers Inc., 2004; pp. 215-229.
3. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
4. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat Rev Cancer 2006; 6: 227-239.
5. Heist RS, Marshall AL, Liu G, et al. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res 2006; 12: 5448-5453.
6. Blons H, Gad S, Zinzindohoue F, et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res 2004; 10: 2594-2599.
7. Meyer E, Vollmer JY, Bovey R, et al. Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 2005; 65: 4261-4272.
8. Gorrin Rivas MJ, Arii S, Furutani M, et al. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology 1998; 28: 986-993.
9. Hahn-Dantona E, Ramos-DeSimone N, Sipley J, et al. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann N Y Acad Sci 1999; 878: 372-387.
10. Liu J, Tsao MS, Pagura M, et al. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer 2003; 42: 335-344.
11. Sauter W, Rosenberger A, Beckmann L, et al. Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 1127-1135.
12. Rollin J, Regina S, Vourc'h P, et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007; 56: 273-280.
13. Su L, Zhou W, Asomaning K, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 2006; 27: 1024-1029.
14. Jormsjo S, Whatling C, Walter DH, et al. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2001; 21: 1834-1839.
15. Shin A, Cai Q, Shu XO, et al. Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 2005; 7: R506-R512.
16. charoenrat P, Leksrisakul P, Sangruchi S. A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer 2006; 118: 2548-2553.
17. Zhu Y, Spitz MR, Lei L, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001; 61: 7825-7829.
18. Bülzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-1110.
19. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4: 31-42.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Jormsjo S, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86: 998-1003.
22. Dunleavey L, Beyzade S, YeS. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 2000; 151: 587-589.
23. THESIAS Software Version 3.1 http://ecgene.net/genecanvas/uploads/ THESIAS3.1/Documentation3.1.htm Date last updated: 2004. Date last accessed: 2008.
24. IHG. Hardy-Weinberg Equilibrium (HWE). http://ihg2.\helmholtz-muenchen. de/cgi-bin/hw/hwa1.pl Date last accessed: October 2008.
25. Matsuno H, Yudoh K, Watanabe Y, et al. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 2001; 28: 22-28.
26. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
27. Galligioni E, Ferro A. Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 2001; 34: Suppl. 4, S3-S7.
28. Inuzuka K, Ogata Y, Nagase H, et al. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 2000; 93: 211-218.
29. Houghton AM, Grisolano JL, Baumann ML, et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 2006; 66: 6149-6155.
30. Hofmann HS, Hansen G, Richter G, et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 2005; 11: 1086-1092.
31. Nenan S, Boichot E, Lagente V, et al. Macrophage elastase (MMP-12): a pro-inflammatory mediator? Mem Inst Oswaldo Cruz 2005; 100: Suppl. 1, 167-172.
32. Mannino DM. COPD and lung cancer have come a long way. . .baby. Am J Respir Crit Care Med 2007; 176: 108-109.
33. Abidi P, Afaq F, Arif JM, et al. Chrysotile-mediated imbalance in the glutathione redox system in the development of pulmonary injury. Toxicol Lett 1999; 106: 31-39.
34. Han MK, Postma D, Mannino D, et al. Gender and COPD: why it matters. Am J Respir Crit Care Med 2007; 176: 1179-1184.